9. AstraZeneca

AstraZeneca's headquarters project has run into years of delays and significant cost overruns, and the drugmaker recently changed contractors. (AstraZeneca)

Headquarters: London, United Kingdom
2017 prescription sales: $19.8 billion
Projected 2024 sales: $31.7 billion

AstraZeneca CEO Pascal Soriot has never wavered in his promise of a turnaround for the long-suffering U.K. drugmaker and projections from Evaluate show that by 2024, that will happen, to a degree. 

It will have 38% greater sales than in 2017 and the No. 9 spot on Evaluate’s list of largest drugmakers in 2024. That year, it'll generate nearly $32 billion in sales.

That will be achieved through a combination of things. The patent loss for Crestor will finally be in the past and no longer a drain on the top line, while the growth areas Soriot has oft-touted will finally pay off.

AZ ranks sixth on Evaluate's list in value creation from recently launched drugs with expected sales of $62.7 billion over the 2017-2024 time period. It also ranks 6th in oncology sales over that period with a forecast of $13.7 billion in 2024, up 19% CAGR.

RELATED: AstraZeneca's new launches shine in Q2 as it inches toward turnaround

The performance will be achieved in great part because of immuno-oncology drug Imfinzi, which Evaluate ranks 6th among new molecular entities approved in 2017 as judged on consensus sales in 2022 at $1.2 billion. Lung cancer drug Tagrisso will also play a role for AstraZeneca.

Imfinzi was the fifth-to-market PD-1/L1 with an approval in bladder cancer but has also picked up an approval since to treat stage 3 lung cancer patients whose tumors can't be removed, a market without a single competitor in sight.

Meanwhile, AstraZeneca also will sit at number five in worldwide sales of anti-diabetic drugs in 2024, up 4% CAGR to $3.2 billion.

RELATED: It's another fail for AstraZeneca's I-O combo, but it may not mean what you think

Also by 2024, AstraZeneca should finally be in its pricey, brand-new headquarters and R&D facility in Cambridge, U.K., which has been plagued by cost overruns and a switch in contractors.

9. AstraZeneca

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.